<DOC>
	<DOCNO>NCT02116660</DOCNO>
	<brief_summary>To evaluate change renal function , efficacy , safety switch combination tenofovir/emtricitabine ( TDF/FTC ) plus protease inhibitor/ritonavir ( PI/r ) combination raltegravir ( MK-0518 ) plus nevirapine plus lamivudine human immunodeficiency virus ( HIV ) -1 participant suppress viremia impaired renal function .</brief_summary>
	<brief_title>Evaluation Renal Function , Efficacy , Safety When Switching From Tenofovir/Emtricitabine Plus Protease Inhibitor/Ritonavir , Combination Raltegravir ( MK-0518 ) Plus Nevirapine Plus Lamivudine HIV-1 Participants With Suppressed Viremia Impaired Renal Function ( MK-0518-284 )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Male , nonpregnant , nonbreastfeeding female No previous history virological failure No previous exposure nonnucleoside reverse transcriptase inhibitor integrase inhibitor No previous history intolerance lamivudine At least 2 documented plasma HIV1 RNA &lt; 50 copies/mL HIV1 &gt; 50 copies/mL 12 month screen Receiving protease inhibitor/ritonavir plus tenofovir/emtricitabine combination least 6 month screen Has major International Antiviral Society ( IAS ) USA mutation genotype test perform start antiretroviral treatment Sexuallyactive participant partner childbearing potential agree use medically acceptable method contraception 2 week Day 1 least 6 month last dose study drug ( postmenopausal woman require use contraception ; sexuallyactive male participant female partner childbearing potential must provide write informed consent information regard pregnancy ) Positive hepatitis B surface antigen ( HBsAg+ ) anticipate need hepatitis C virus treatment Liver cirrhosis Has history diabetes mellitus , define initiation antidiabetic treatment verification diabetes case report form Has cancer , exclude stable Kaposi Sarcoma Allergy sensitivity investigational product excipients Female participant nurse Female participant pregnant intend become pregnant Has active Acquired Immunodeficiency Syndrome ( AIDS ) define event except stable Kaposi Sarcoma HIV Wasting Syndrome Received investigational drug within 30 day screen Participated clinical trial within 30 day sign informed consent current trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>